窪蹋勛圖厙

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 窪蹋勛圖厙 News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Nov 10 2025

Full Issue

New Cholesterol Breakthroughs Help Reduce LDL Levels, Heart Attack Risk

Merck's new pill, enlicitide, and Amgen's longtime Repatha shot are showing heart attack risk-lowering potential, and researchers have made progress on the gene-editing front.

Merck, the company that introduced statins to the world nearly 40 years ago, has a new, intensely powerful pill that can slash levels of dangerous LDL cholesterol to levels almost never seen in adults. The new pill, enlicitide, blocks a liver protein, PCSK9, that slows the bodys ability to clear cholesterol. With most PCSK9 blocked, LDL levels plummet and rates of heart attacks and strokes in high risk patients fall by up to 20 percent in just the first year. At least six million adults in the United States are eligible for drugs that block PCSK 9. (Kolata, 11/8)

A cholesterol-lowering injection thats been on the market for nearly a decade has now shown its power to cut cardiovascular events in people considered at high risk but who havent yet suffered a heart attack or stroke. (Cooney, 11/8)

With a snip of a gene, doctors may one day permanently lower dangerously high cholesterol, possibly removing the need for medication, according to a new pilot study published Saturday in the New England Journal of Medicine. (LaMotte, 11/8)

A statin isnt the only answer anymore to lowering cholesterol. The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades. But they dont work for everyone, and can only reduce harmful bad cholesterol so much. (McKay, 11/8)

In science news

He co-discovered DNAs structure but later engaged in rank racism and sexism. (Begley, 11/7)

The laws of inheritance are quite unknown, Charles Darwin acknowledged in 1859. The discovery of DNAs shape altered how we conceived of life itself. (Zimmer, 11/7)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, June 5
  • Thursday, June 4
  • Wednesday, June 3
  • Tuesday, June 2
  • Monday, June 1
  • Friday, May 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 窪蹋勛圖厙
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

穢 2026 KFF